|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> Pancreatic cancer (PC); peripheral blood lymphocytes (PBLs); A Disintegrin and Metalloproteinase Domain 10 (ADAM10); MHC class I-related molecule A (MICA); soluble MICA (sMICA); membrane MICA (mMICA); Hypoxia-inducible factor 1-alpha (HI1FA); long non-coding RNAs (lncRNAs); non-coding RNAs (ncRNAs); natural killer (NK); Haematoxylin and eosin (H&E); Immunohistochemistry (IHC); natural killer group 2 member D (NKG2D).
|
31402756 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein.
|
31367258 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
miR-212 regulated by HIF-1α promotes the progression of pancreatic cancer.
|
30867721 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
P4HA1/HIF1α feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
|
31239153 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
To study the angiogenic role of HIF1A, and specifically probe whether tumors are able to use alternative pathways in its absence, we created a xenograft mouse tumor model of pancreatic cancer lacking HIF1A.
|
31585939 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
STIM1 and HIF-1α expression was tested using immunohistochemistry in tissue microarray (TMA) including pancreatic cancer and matched normal pancreatic tissues, and their relationships with clinicopathological parameters were statistically analyzed. q-PCR, Western blot, ChIP, and luciferase assay were employed to 030 analyze transcriptional regulation between HIF-1α and STIM1 in pancreatic cancer PANC-1 cells.
|
31119050 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, this study proposes a potential molecular mechanism illustrating that β‑elemene can block the HIF1A/VEGFA pathway, thereby inhibiting the generation of peritoneum effusion in pancreatic cancer based on network pharmacology analysis, and further highlights the importance of targeting the HIF1A/VEGF pathway as a therapeutic approach to treat peritoneum effusion in patients with pancreatic cancer.
|
31638231 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
More importantly, inhibition of HIF-1α suppressed the metastasis of pancreatic cancer and prolonged survival time.
|
31100311 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pancreatic cancer cells (BxPC-3 cells) were transfected with short hairpin RNA targeting the HIF-1α.
|
31241439 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers.
|
30481072 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions</b>: These results suggest that feedback between MTA2TR and HIF-1α may play a key role in regulating PC tumorigenesis, thus potentially highlighting novel avenues PC treatment.
|
31410216 |
2019 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Statistcal analysis was performed to explore the relationship between HIF-1α expression and pathological features of patients with pancreatic cancer.
|
30455857 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previous research principally focused on hypoxia-inducible factor-1 alpha (HIF-1α) and HIF-2α (HIF1A and EPAS1) as the major hypoxia-associated transcription factors in pancreatic cancer.
|
28928287 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the increased secretion of SHH by HIF-1 is potentially responsible for the formation of detrimental and stroma-rich microenvironments in pancreatic cancers, therefore providing a rational basis to target it in cancer therapy.
|
29535824 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
ROS mediated EGFR/MEK/ERK/HIF-1α Loop Regulates Glucose metabolism in pancreatic cancer.
|
29702094 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer.
|
29476053 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
|
29758199 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our study demonstrated that HGF/c-MET modulates tumor metabostemness by regulating YAP/HIF-1α and may hold promise as a potential therapeutic target against pancreatic cancer.
|
30056064 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that pancreatic cancer (PDAC) progression and metastasis could be be targeted by P-AscH<sup>-</sup> via H<sub>2</sub>O<sub>2</sub>-mediated inhibition of HIF-1α stabilization.
|
29396728 |
2018 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.
|
28697344 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings revealed the function of RGC-32 in hypoxia-induced EMT and may have identified a novel link between HIF-1α and EMT for pancreatic cancer therapy.
|
28810656 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Above all, these findings provided insights on the functional mechanism of miR-142, suggesting that the miR-142/HIF-1α axis may interfere with the proliferative and invasive properties of pancreatic cancer cells, and indicated that miR-142 could be a potential therapeutic target for pancreatic cancer.
|
28069592 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using Western blotting, we demonstrated that emodin and rhein decreased HIF-1α expression in MiaPaCa2 and four other human pancreatic cancer cell lines.
|
29152137 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α.
|
29038348 |
2017 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer.
|
28801636 |
2017 |